Other

Altera Corporation

Cytec Technology Corporation

Cytec Industries Inc.

University of Virginia Patent Foundation

Inspectron Corporation

Sloan-Kettering for Cancer Research

Cytec Engineered Materials Limited

Price, Richard Louis

Richard Louis Price

Dominique Ponsolle

Robert Blackburn

Marc Doyle

Abdel Abusafieh

William Alan Jacobs

Carmelo Luca Restuccia

Carmelo LoFaro

Mitchell Smith

Steven Perry

Patrick Terence McGrail

Jonathan C Park

Paul Mark Cross

Gregor Nixon

Andrew Hall

Alasdair Scott

Chris Dettmar

Maxwell Zachary Price

Larry Kong

Lingli Wang

Lawrence David Landis

Joel M Linden

Billy D Harmon

Mark Roman

Brent F Lyons

Amy L Tucker

Rebecca Youkey

Daniel T Belville

Rene Todoverto

Disclosed are methods of treating a patient having Major Depressive Disorder (MDD). The methods include administering to the patient a therapeutically effective amount of bupropion hydrobromide in extended-release form. The methods are more therapeutically effective in treating MDD than administration of an equivalent plasma dose of bupropion hydrochloride in extended-release form. Optionally, in addition, the therapeutically effective amount of bupropion hydrobromide reduces the incidence of one or more adverse events (anxiety, agitation and/or insomnia), when compared to the administration of the equivalent plasma dose of bupropion hydrochloride in extended-release form.

Therapeutic methods using bupropion hydrobromide to treat Major Depressive Disorder

Disclosed are methods of treating a patient having Major Depressive Disorder (MDD) or Treatment Resistant Depression (TRD). The methods include administering to the patient a therapeutically effective amount of bupropion hydrobromide in extended-release form. The methods are more therapeutically effective in treating MDD or TRD than administration of an equivalent plasma dose of bupropion hydrochloride in extended-release form. In addition or alternatively, the therapeutically effective amount of bupropion hydrobromide reduces the incidence of one or more adverse events (anxiety, agitation and/or insomnia), when compared to the administration of the equivalent plasma dose of bupropion hydrochloride in extended-release form.

Therapeutic methods using bupropion hydrobromide

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

Treatment of autism spectrum disorder and associated symptoms

Disclosed herein is a dry, self-supporting fibrous material, the fibers of which have been treated with a binder composition. The fibrous material can be slit into tapes or tows that are suitable for use in an Automated Tape Laying (ATL) or Automated Fiber Placement (AFP) process. This fibrous material is suitable for forming preforms which are configured to receive a matrix resin by resin infusion in the manufacturing of structural composite parts.

Dry fibrous material for subsequent resin infusion

A method for treating a patient having one or more of anxiety, hypersensitivity, restricted areas of interest, repetitive behaviors, irritability and emotional lability, or otherwise requiring a calming effect, is disclosed. The method includes administering to the patient a plurality of comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol.

Inositol-containing comestible units and methods of treatment using the same

Embodiments of the invention are directed to metal- or metal alloy-coated sheet materials (hereinafter, 'metal-coated sheet material') including, but not limited to, fabrics and veils which have a metal content of between one (1) and fifty (50) grams per square meter (gsm). The metal-coated sheet materials may be used as-is or in conjunction with prepregs, adhesives or surfacing films to provide lightning strike protection (LSP) and/or bulk conductivity, among other benefits, to the resultant composite article. In one embodiment, the metal-coated sheet material is impregnated with a resin. According to embodiments of the invention, a metal is applied to one or two sides of the fabric or veil by a physical vapor deposition coating process. The resultant metal-coated fabric or veil may be used as a carrier in surfacing films to impart surface conductivity; may be used as a carrier in adhesives to form conductive adhesive-bonded joints; may be interleaved (one or more metal-coated veils) between layers of prepreg to impart surface and/or bulk conductivity as well as toughness; or may be used to fabricate composite articles.

Methods of imparting conductivity to materials used in composite article fabrication and materials thereof

Embodiments of the invention are directed to resin-soluble thermoplastic veils for use in liquid resin infusion processes, methods of manufacturing resin-soluble thermoplastic veils for use in liquid resin infusion processes, and methods of manufacturing composite articles using resin-soluble thermoplastic veils for use in liquid resin infusion applications. The resin-soluble thermoplastic veils according to embodiments of the invention and of which function as a toughening agent in composites having the veil incorporated therein have improved characteristics including, but not limited to, increased uniformity and decreased thickness relative to prior art veils. These characteristics translate into improvements in the processing of a composite article including, but not limited to, a substantial or complete elimination in premature dissolution of the veil during cure. The resultant composite article also realizes improvements including, but not limited to, distribution evenness of the toughening agent throughout the composite.

Resin-soluble veils for composite article fabrication and methods of manufacturing the same

Connector assembly

A method for treating a patient having ASD is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form in combination with a therapeutically effective amount of inositol.

Treatment of autistic spectrum disorder

A thermoplastic polymer toughening material in the form of polymeric fibers produced by mixing at least one epoxy curing agent and a thermoplastic polyaromatic polymer to form an admixture, and producing polymeric fibers from the admixture, wherein the thermoplastic polymer toughening material does not include an epoxy resin, and is soluble in an epoxy resin at a temperature lower than a dissolving temperature required by the thermoplastic polymer toughening material without epoxy curing agent.

Multifunctional additives in engineering thermoplastics

A method for treating a patient having P.R.I.C.E. Syndrome is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form.

Diagnosis and treatment of P.R.I.C.E. syndrome

Techniques and design methodologies for using a single mask set to create devices of different sizes are disclosed. A mask with a plurality of tiles is disclosed. Each of the tiles has a number of fixed resource blocks, multiple logic blocks and is surrounded by a scribe region. The tiles may be connected to one or more adjacent tiles through interconnect lines that enable the fixed resource blocks and logic blocks in one tile to communicate with the fixed resource and logic blocks in an adjacent tile. The mask set may be used to produce devices of different sizes. Using a mask set that can handle a variety of design sizes with varying resources may in turn reduce mask cost.

Using a single mask for various design configurations

Growing community of inventors

Suffern, NY, United States of America

Richard Louis Price